首页> 外文期刊>Human vaccines & immunotherapeutics. >Safety, immunization coverage and determinants of a new kind of Hepatitis B vaccine firstly applied in Ningbo, China
【24h】

Safety, immunization coverage and determinants of a new kind of Hepatitis B vaccine firstly applied in Ningbo, China

机译:新型乙型肝炎疫苗的安全性,免疫范围和决定因素在中国宁波首次应用

获取原文
获取原文并翻译 | 示例
           

摘要

Evaluate safety and immunization coverage of a new kind of recombinant Hepatitis B vaccine (HepB) in Ningbo city, China. Two groups were carried out in 2 of 11 randomly selected countries in Ningbo in 2009. All of the infants born from July 1 to December 31, 2009 were enrolled as subjects and received 3 doses of HepB at 0, 1, 6 month. Control group (N = 3452) received current HepB derived from Saccharomyces Cerevisiae Yeast (HepB made by recombinant DNA techniques in Saccharomyces Cerevisiae Yeast, HepB-SCY; 5 g/0.5 ml per dose) and experimental group (N = 5104) received the new kind of HepB derived from Hansenula polymorpha Yeast (HepB made by recombinant DNA techniques in Hansenula polymorpha Yeast, HepB-HPY; 10 g/0.5 ml per dose). 3-dose and timely birth dose (TBD) coverage were available and compared between 2 groups. Standard structuredquestionnaires were applied to record information from parents and hospitals for selecting determinants of coverage. The data were analyzed using stepwise multiple logistic regression models. After each dose, HepB-related adverse events (AEs) and recta-temperature were recorded for 7days. 3-dose coverage in control group (89.98%) was higher than that in experimental group (2 = 575.1173, P < 0.0001). TBD coverage in control and experimental group were 98.41% and 98.53%, respectively. No statistically significant difference in TBD coverage was found between 2 groups (2 = 0.0623, P = 0.8029). A total of 9 local AEs were reported, 4 for control group and 5 for experimental group. The percentages of subjects reporting AEs were similar across the 2 vaccination groups. No serious or immediate reactions were found in this study. From logistic models, receiving 10 g vaccine (odds ratio [OR]:0.38; 95% confidence interval [95%CI]: 0.34-0.44) and mother migrating from other cities (OR: 0.45; 95%CI: 0.42-0.47) were the determinants for non-acceptance of 3 doses of HepB; infants born from low grade hospitals and native mothers contributed to administrate the TBD.
机译:在中国宁波市评估一种新型重组乙型肝炎疫苗(HepB)的安全性和免疫覆盖率。 2009年在11个随机选择的国家/地区中的2个国家/地区进行了两组研究。所有2009年7月1日至12月31日出生的婴儿均作为研究对象,分别在0、1、6个月接受3剂HepB。对照组(N = 3452)接受当前来自酿酒酵母酵母的HepB(通过重组DNA技术在酿酒酵母酵母中制备的HepB,HepB-SCY;每剂量5 g / 0.5 ml),而实验组(N = 5104)接受新的一种来源于多形汉逊酵母的HepB(通过多形汉逊酵母中的重组DNA技术制备的HepB,HepB-HPY;每剂10 g / 0.5 ml)。可获得3剂量和及时的出生剂量(TBD)覆盖率,并在两组之间进行比较。应用标准的结构问卷来记录父母和医院的信息,以选择覆盖范围的决定因素。使用逐步多元逻辑回归模型分析数据。每次给药后,记录HepB相关不良事件(AEs)和直肠温度7天。对照组三剂量覆盖率(89.98%)高于实验组(2 = 575.1173,P <0.0001)。对照组和实验组的TBD覆盖率分别为98.41%和98.53%。两组之间的TBD覆盖率无统计学差异(2 = 0.0623,P = 0.8029)。总共报告了9种局部AE,对照组4种,实验组5种。在两个疫苗接种组中,报告不良事件的受试者百分比相似。在这项研究中没有发现严重或立即的反应。从逻辑模型中,接收10克疫苗(赔率[OR]:0.38; 95%置信区间[95%CI]:0.34-0.44),母亲从其他城市移民(OR:0.45; 95%CI:0.42-0.47)是不接受3剂HepB的决定因素;低级医院出生的婴儿和当地母亲为TBD的管理做出了贡献。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号